As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

The optimal hydroxychloroquine blood level in lupus is between 750 ng/mL and 1,150 ng/mL, which can help prevent active ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Systemic Lupus Erythematosus is one of the most complex autoimmune diseases seen in modern medicine, affecting multiple organs and presenting differently from one patient to another. Often referred to ...

It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

USA: Researchers have reported that low vitamin D levels are strongly linked to a higher risk of death and cardiovascular ...

The prevalence of autoimmune diseases is increasing, especially in women, and the ongoing winter season, along with high ...